Table 4.

ABCB1 polymorphisms and taxane‐induced toxicities

	2677 G > T				3435 C > T
AE	TT (n = 40)	TG (n = 53)	GG (n = 29)	P‐value*	TT (n = 17)	TC (n = 54)	CC (n = 51)	P‐value*
Constipation	0 (0%)	2 (3.8%)	2 (6.9%)	0.497	2 (11.8%)	2 (3.7%)	0 (0%)	0.714
Diarrhea	2 (5.0%)	3 (5.7%)	0 (0%)	0.270	1 (5.9%)	4 (7.4%)	0 (0%)	0.244
Leucopenia	20 (50.0%)	31 (58.5%)	12 (41.3%)	0.323	10 (58.8%)	28 (51.9%)	25 (49.0%)	0.782
Neutropenia	19 (47.5%)	31 (58.5%)	12 (41.3%)	0.293	9 (52.9%)	29 (53.7%)	24 (47.1%)	0.779
Thrombocytopenia	2 (5.0%)	5 (9.4%)	3 (10.3%)	0.905	1 (5.9%)	5 (9.3%)	4 (7.8%)	0.900
Anemia	2 (5.0%)	6 (11.3%)	2 (6.9%)	0.523	2 (11.8%)	6 (11.1%)	2 (3.9%)	0.344
Nausea	15 (37.5%)	23 (43.4%)	10 (34.5%)	0.864	9 (52.9%)	21 (38.9%)	18 (35.3%)	0.598
Vomit	5 (12,5%)	7 (13.2%)	3 (10.3%)	0.731	2 (11.8%)	8 (14.8%)	5 (9.8%)	0.874
Myalgia	4 (10%)	5 (9.4%)	2 (6.9%)	0.675	1 (5.9%)	4 (7.4%)	6 (11.8%)	0.562
Neuritis	19 (47.5%)	14 (26.4%)	5 (17.2%)	0.073	15 (88.2%)	12 (22.2%)	11 (21.6%)	0.004
Liver dysfunction	6 (15.0%)	10 (18.9%)	4 (13.8%)	0.903	3 (17.6%)	9 (16.7%)	8 (15.7%)	0.962

^* P‐value was calculated by chi‐squared trend analysis.